Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
about
Role of mTOR Inhibitors in Kidney DiseaseSirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular EffectsImmunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantationSystemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsReviewing 15 years of experience with sirolimusNew cell-signaling pathways for controlling cytomegalovirus replication.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic riskEfficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant RecipientsAn evaluation of sirolimus in renal transplantation.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.mTOR inhibitors in pediatric kidney transplantation.Prevention of cytomegalovirus following solid organ transplantation: a literature review.The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancymTOR inhibitors and renal allograft: Yin and Yang.Evolving perspectives of mTOR complexes in immunity and transplantation.Everolimus and sirolimus in transplantation-related but different.Xenotransplantation and porcine cytomegalovirus.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.Torque Teno Virus Load-Inverse Association With Antibody-Mediated Rejection After Kidney Transplantation.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial.Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.2-(2,4-Dioxy-1,2,3,4-Tetrahydropyrimidin-1-yl)-N-(4-Phenoxyphenyl)-Acetamides as a Novel Class of Cytomegalovirus Replication Inhibitors.De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation.Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.Optimising the use of mTOR inhibitors in renal transplantation.Interactions between anti-infective agents and immunosuppressants in solid organ transplantation.Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus.Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.Measuring T-cell responses against LCV and CMV in cynomolgus macaques using ELISPOT: potential application to non-clinical testing of immunomodulatory therapeutics.Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.
P2860
Q26747506-2BED3164-EB68-456F-895B-88D510B2B4CDQ26749011-C129D23E-6A2C-4286-AE53-9F01F2F5D5B4Q26751433-375DDA14-6C92-413A-A2D0-8783EA186FC4Q26823023-B0039065-B087-43AB-B990-E9901C04CD4DQ28080955-CF61E089-244D-4FCA-A928-DAD57CDCCE8EQ34793671-CB2712E5-5671-4625-868F-43F00EE89BE8Q35231363-96627399-973E-47CD-9381-7B601DA46376Q35257624-ACBCC52B-5205-4E82-9CFE-B529312A342FQ35649082-1A0FA12D-27A0-4EA7-9898-9D71B7B584EEQ35788609-DCF0915D-1A0D-451C-8EF8-A4E1D393819FQ38038696-9240F9C0-3813-494D-85B7-6B5C892163DFQ38061056-596A7ED3-3DE9-40DC-8DD1-170677EADDD6Q38112331-7265ACE1-9DAA-4D8E-BF96-1B72C967424BQ38124439-28FE9017-92AF-47E0-8000-D13D28CECED2Q38190674-C13A60F8-A03F-437F-8699-0E2FCCCE76E7Q38209973-DC6FF867-6FEF-4E29-9608-FE8664F8B4D8Q38367426-AA4E3862-CAB3-447E-92A4-C6925646F971Q38442560-86018B1E-E7B1-415C-AC9F-86708519BD17Q38588603-C37C669D-7020-4CAF-9318-55778C93B647Q38711763-D75A8D6D-1527-48D1-946F-6832BB703631Q38747503-597C54FD-7448-4A64-8899-27104441B5E7Q38831291-CFB2534E-C588-4154-AC20-F14EE42FF590Q38875887-6BC8EA8E-42F7-4F63-AD65-E32075E0F77FQ38914374-0A97A034-117D-4DFC-BCB1-8645FA4410EFQ38947867-2310B672-98A5-4D79-AC8A-FFC8E1DBA561Q38962103-05902E95-9A6B-4567-B28A-A593DED8316CQ40141033-9027F9BB-9715-443B-8747-1F83C3F413F0Q40267366-C58BFDE0-B34D-49CE-BC0D-C2A919842171Q40483831-2FFBCFB3-E07D-49F0-B82C-3997D1405840Q40537018-BE3AF854-D496-4E55-B993-1FEF2BA75F2FQ40856064-7A016989-4741-4367-A485-811530091748Q40957975-A0CEDA6C-2A99-4B63-944F-F514604F782BQ41019245-5893D455-2289-47B4-A3EC-353E6B43A517Q41218897-83FC3A74-F4A7-4653-B0D0-85E48D939EBAQ41928074-843CFB97-7638-47B9-B8C8-A69B9A01F20EQ42272268-1B008AFA-9C09-4025-93F2-9426E2D49805Q42284856-47C072F7-80D6-4B5E-90DF-70092D254DDBQ43485988-60D2A4CC-CB1A-4D98-9252-7FE5493B4E3CQ45905220-8DEB09B6-E5FE-47ED-962D-85E94077C95DQ47309233-A886D238-D725-44EC-BD02-30FACDC31ED0
P2860
Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Review of cytomegalovirus infe ...... o renal transplant recipients.
@en
type
label
Review of cytomegalovirus infe ...... o renal transplant recipients.
@en
prefLabel
Review of cytomegalovirus infe ...... o renal transplant recipients.
@en
P2093
P1433
P1476
Review of cytomegalovirus infe ...... o renal transplant recipients.
@en
P2093
Björn Nashan
Daniel C Brennan
Fuad Shihab
Jacques Dantal
Lionel Couzi
Marcus D Säemann
Nicolas J Mueller
Robert Gaston
Shamkant Mulgaonkar
P304
P356
10.1097/TP.0B013E31824810E6
P577
2012-06-01T00:00:00Z